We’re busy reviewing the evidence on Pomi-T®. While we’re working, we share the original summary from our predecessor website, Beyond Conventional Cancer Therapies.

Please consider supporting our update and revision to this information.

Pomi-T®

Key Points

  • Before using this therapy, consult your oncology team about interactions with other treatments and therapies. Also make sure this therapy is safe for use with any other medical conditions you may have.
  • Pomi-T is a food supplement capsule containing green tea, pomegranate seed extract, broccoli extract and turmeric.
  • Pomi-T interests BCCT because of the impressive results of a trial evaluating its use in men with prostate cancer undergoing active surveillance or watchful waiting.
  • It is listed and described in the NCI’s PDQ Prostate Cancer, Nutrition, and Dietary Supplements as one of the multicomponent complementary therapies used in preventing and treating prostate cancers.
  • Although initial research is promising, no clinical evidence yet shows that Pomi-T has any impact on cancer outcomes.
  • Pomi-T in clinical trial was well tolerated, although some people may be hypersensitive to one or more components in Pomi-T. Some of the components can potentially interact with prescription drugs. Consult with your pharmacist for interactions, and discuss using Pomi-T with your doctor.

Pomi-T® is a food supplement capsule containing green tea, pomegranate seed extract, broccoli extract and turmeric. The individual components in Pomi-T are each rich in polyphenols, natural plant-based phytochemicals that are associated with lowering risk for a number of chronic illnesses and are known for anticancer effects.

Pomi-T was developed by a team of doctors, scientists and nutritionists led by an oncologist from Cambridge University for a national randomized control trial in the United Kingdom (UK). Classified in the UK as a food supplement and not as a medicinal product, Pomi-T cannot legally be recommended for any medical condition or claim any health benefits. However, it contains a combination of food extracts that are included in several integrative cancer care protocols for prostate and other cancers (see our related pages section for more information).

Treating the Cancer

Working against cancer growth or spread, improving survival, or working with other treatments or therapies to improve their anticancer action

Clinical Evidence

Pomi-T was tested in a small study of men with early-stage prostate cancer in active surveillance or watchful waiting. Because rising prostate-specific antigen (PSA) levels are a marker of potential cancer activity, the researchers tracked these levels. After six months, the Pomi-T treatment group’s PSA rose by 14.7 percent, but the levels in the group not receiving Pomi-T rose by 78.5 percent.1 The researchers concluded that taking Pomi-T had a significant short-term favorable effect on PSA levels, slowing the rise dramatically..2

Although one small clinical study showed significant effects of Pomi-T on PSA levels, it was of short duration (six months), and no impact on cancer incidence, quality of life or mortality was established.4 Pomi-T shows promise, but as yet no clinical evidence of impact on cancer is available..5

Components of Pomi-T

The individual ingredients in Pomi-T are all considered to be rich in polyphenols, natural plant-based phytochemicals that are associated with lowering risk for a number of chronic illnesses as well as having anticancer effects, as described in the study of Pomi-T:3

In lab studies, pomegranate has shown anticancer effects in breast and prostate cancer cells. In human studies of prostate cancer, it prolonged PSA doubling and improved markers of oxidative stress.

  • In lab studies, green tea has shown anticancer properties in breast and prostate cancer cells. Men given an extract of green tea saw a significant reduction in cancer growth factors and a beneficial effect on PSA.
  • In the lab, broccoli inhibits growth of cancer cells and promotes apoptosis (programmed cell death). In a human study, broccoli “quieted” cancer promoting genes and “turned on” cancer suppressing genes. See the Diindolylmethane (DIM) page for more information.
  • Curcumin (in turmeric) has shown several anticancer effects as well as anti-inflammatory effects. It has halted the growth of stem cells that give rise to breast cancer cells while leaving normal breast cells alone.
  • “Finally, all four ingredients also have some antioxidant properties that are thought to protect the DNA against oxidative damage from ingested or environmental carcinogens, although this precise mechanism has not been confirmed clinically.”

Lab and Animal Evidence

Click or tap to open.

Optimizing Your Terrain

Lab and Animal Evidence

Click or tap to open.

Access

Pomi-T is a food supplement and doesn’t require a prescription. It is generally available at retail pharmacies, supplement stores and online.

Cautions

Because Pomi-T doesn’t contain the sugar in pomegranate juice, use is generally appropriate for patients with diabetes.

Safety of Pomi-T in pregnancy hasn’t been established. Safety recommendations for green tea, pomegranate seed extract, broccoli extract and turmeric should be followed.

Side Effects/Adverse Events

Pomi-T was well tolerated in the study, although a few side effects were noted compared to a control:

  • More flatulence and loose bowels
  • Mild indigestion, which disappeared if Pomi-T was taken with food

Drug Interactions

Pomegranate has the potential to interact with some drugs, such as warfarin, anti-hypertensives or anti-convulsants. For more information on potential drug interactions see Pomi-T website FAQ’s: Does Pomi-T interact with other drugs

Although not substantiated in humans, in lab studies, high doses of polyphenols can have anti-oxidant effects that could possibly reduce the action of chemotherapy. The Pomi-T website advises that until this issue is resolved, it’s best to avoid taking Pomi-T one day before and three days after the administration of chemotherapy.

People can be hypersensitive to one or more of the ingredients in Pomi-T. It is contraindicated in people with allergies to pomegranate or caffeine. For more safety information on Pomi-T, visit the Pomi-T website.

Dosing

CancerChoices does not recommend therapies or doses, but only provides information for patients and providers to consider as part of a complete treatment plan. Patients should discuss therapies with their physicians, as contraindications, interactions and side effects must be evaluated. Levels of active ingredients of natural products can vary widely between and even within products. See Quality and Sources of Herbs, Supplements and Other Natural Products.

The Pomi-T official website contains a number of tips on dosing as well as improving the absorption and bioavailability of Pomi-T. The UK site also describes an i-Phone app created to help patients calculate their PSA doubling time between two time points. See the Pomi-T FAQ’s page (Q. How can I accurately follow my PSA doubling time?).

Integrative Programs, Protocols and Medical Systems

For more information about programs and protocols, see our Integrative Programs and Protocols page.

Pomi-T is not yet listed in any of the protocols or systems that BCCT references, although several of its constituent ingredients are used in protocols.

Commentary

From CancerChoices staff, January 4, 2018: In a 2013 post, integrative oncologist Dr. Brian Lawenda cautions, “POMI-T is NOT A TREATMENT FOR PROSTATE CANCER. Make sure you have first discussed this with your cancer care team before taking POMI-T as the individual ingredients have the potential to interact with other therapies you may be receiving.”6 Thus, although Pomi-T has been shown to reduce PSA in early stage prostate cancer, no evidence to date indicates it could stand alone as a treatment for prostate cancer.

Note: CancerChoices has not conducted an independent review of research of Pomi-T. We have drawn from the following sources to create this summary:

Resources

References

  1. Excellus Health Plan, Inc. Medical Policy. Subject: Hyperthermia as a Cancer Treatment. May 17, 2018. Viewed April 22, 2019.
  2. American Cancer Society. Hyperthermia to Treat Cancer. May 3, 2016. Viewed April 23, 2019.
  3. Foster JM, Sleightholm R et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Network Open. 2019 Jan 4;2(1):e186847.
  4. National Cancer Institute. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version. US Department of Health and Human Services. February 1, 2019. Viewed April 22, 2019.
  5. Marlene and Stewart Greenbaum Comprehensive Cancer Center. Cytoreductive Surgery and HIPEC—FAQs. University of Maryland Medical Center. Viewed April 22, 2019.
  6. American Cancer Society: Hyperthermia to Treat Cancer. May 3, 2016. Viewed April 22, 2019.
  7. National Cancer Institute. Hyperthermia in Cancer Treatment. US Department of Health and Human Services. August 31, 2011. Viewed April 22, 2019.
  8. Yagawa Y, Tanigawa K, Yamamoto M. Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. Journal of Cancer Metastasis and Treatment. 2017;3:218-230.
  9. Hildebrandt B, Wust P et al. The cellular and molecular basis of hyperthermia. Critical Reviews in Oncology/Hematology. 2002 Jul;43(1):33-56.
  10. Clinical Practice Guidelines in Oncology. Ovarian Cancer: Including Fallopian Tube Cancer and Primary Peritoneal Cancer: NCCN Evidence BlocksTM. National Comprehensive Cancer Network. Version 1.2019—March 8, 2019. Viewed April 23, 2019.
  11. van der Zee J. Heating the patient: a promising approach? Annals of Oncology. 2002 Aug;13(8):1173-84.
  12. van der Zee J. Heating the patient: a promising approach? Annals of Oncology. 2002 Aug;13(8):1173-84; Wust P, Hildebrandt B et al. Hyperthermia in combined treatment of cancer. Lancet Oncology. 2002 Aug;3(8):487-97; Falk MH, Issels RD. Hyperthermia in oncology. International Journal of Hyperthermia. 2001 Jan-Feb;17(1):1-18.
  13. Masunaga SI, Hiraoka M et al. Phase I/II trial of preoperative thermoradiotherapy in the treatment of urinary bladder cancer. International Journal of Hyperthermia. 1994;10(1):31-40.
  14. van der Zee J, González González D et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet (London, England). 2000;355(9210):1119-1125.
  15. Rousskow S. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. BMJ Open. 2017;7(11)e017387
  16. Van Gool SW, Makalowski J et al. The induction of immunogenic cell death (ICD) during maintenance chemotherapy and subsequent multimodal immunotherapy for glioblastoma (GBM). Austin Oncology Case Reports. 2018;3(1):1010.
  17. Hegewisch-Becker S, Hossfeld DK et al. Addition of hyperthermia. heat potentiates cancer therapy. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32; Vernon CC, Hand JW et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Journal of Radiation Oncology, Biology, Physics. 1996:35(4):731-744.
  18. Jones EL, Prosnitz LR et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clinical Cancer Research. 2004;10:4287-4293.
  19. Vujaskovic Z, Kim DW et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia. 2010;26(5):514-521.
  20. van der Zee J, González González D et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet (London, England). 2000;355(9210):1119-1125.
  21. Hegewisch-Becker S, Hossfeld DK et al. Addition of hyperthermia. heat potentiates cancer therapy. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32; Lutgens L, Koper P et al. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: results of the randomized RADCHOC trial. Radiotherapy and Oncology. 2016(120):378-382; Franckena M, Stalpers LJA et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. International Journal of Radiation Oncology, Biology, Physics. 2008;70(4):1176-1182; Harima Y, Nagata K et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. International Journal of Hyperthermia. 2001;17(2):97-105.
  22. Zolciak-Siwinska A, Piotrkowicz N et al. HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy—a phase III study. Radiotherapy and Oncology. 2013;109(2):194-199; Minnaar C, Baeyens A, Kotzen J. Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemoradiotherapy for cervical cancer patients in South Africa. European Journal of Medical Physics. 2016;32(2):151-152; Westermann AM, Jones EL et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer. 2005;104(4):763-770.
  23. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. International Journal of Hyperthermia. 1990;6(5):881-890; van der Zee J, González González D et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet (London, England). 2000;355(9210):1119-1125..
  24. Hager ED, Dziambor H et al. Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer. Anticancer Research. 1999;19(4C):3403-3408; Davenport L. CRC with peritoneal metastases: CRS-HIPEC refinements. Medscape Oncology. July 6, 2020. Viewed July 13, 2020.
  25. Kuwano H, Sumiyoshi K et al. Preoperative hyperthermia combined with chemotherapy and irradiation for the treatment of patients with esophageal carcinoma. Tumori. 1995;81(1):18-22.
  26. Liming S, Yongling J, Qiner W, Xianghui D. Regional hyperthermia combined with radiotherapy for esophageal squamous cell carcinoma with supraclavicular lymph node metastasis. Oncotarget. 2017 Jan 17;8(3):5339–5348.
  27. Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial. Journal of Cancer Research and Therapeutics. 2010;6(4):592-496.
  28. Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with recurrent carcinomas of the head and neck with metastatic cervical lymph nodes. International Journal of Hyperthermia. 1999;15(5):371-381; Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Radiotherapy and Oncology. 1999;50(1):103-106.
  29. Hiraki Y, Nakajo M et al. Effectiveness of RF capacitive hyperthermia combined with radiotherapy for stages III and IV oro-hypopharyngeal cancers: a non-randomized comparison between thermoradiotherapy and radiotherapy. International Journal of Hyperthermia. 1998;14(5):445-457.
  30. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. International Journal of Radiation Oncology, Biology, Physics. 1994;28(1):163-169.
  31. Datta NR, Bose Ak, Kapoor HK, Gupta S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. International Journal of Hyperthermia. 1990;6(3):479-486.
  32. Gadaleta-Caldarola G, Infusino et al. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: a phase II study. Oncology Letters. 2014;8(4):1783-1787.
  33. Ferrari VD, Ponti SD et al. Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study. Journal of Clinical Oncology. 2007;5(18):suppl15168.
  34. Ryu J, Kangwook L et al. Patient with unresectable cholangiocarcinoma treated with radiofrequency hyperthermia in combination with chemotherapy: a case report. Integrative Cancer Therapies. 2018;17(2):558-561.
  35. Lee DY, Park JS et al. The outcome of the chemotherapy and oncothermia for far advanced adenocarcinoma of the lung: case reports of four patients. Advances in Lung Cancer. 2015;4:1-7.
  36. Karasawa K, Muta N et al. Thermoradiotherapy in the treatment of locally advanced nonsmall cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 1994;30(5):1171-1177. 
  37. Shen H, Li XD et al. The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. International Journal of Hyperthermia. 2011;27(1):27-32;
  38. Hegewisch-Becker S, Hossfeld DK et al. Addition of hyperthermia. heat potentiates cancer therapy. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32; Overgaard J, Gonzalez Gonzalez D et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 1996;12(1):3-20. 
  39. van der Horst A, Versteijne E et al. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. International Journal of Hyperthermia. 2018;34(7):969-979. 
  40. Royce PL, Ooi JJY, Sothilingam S, Yao HH. Survival and quality of life outcomes of high-intensity focused ultrasound treatment of localized prostate cancer. Prostate International. 2020;8(2):85-90.
  41. Abreu AL, Peretsman S et al. High intensity focused ultrasound hemigland ablation for prostate cancer: initial outcomes of a United States series. Journal of Urology. 2020;204(4):741-747.
  42. Angele MK, Albertsmeier M et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Annals of Surgery. 2014 Nov;260(5):749-54; discussion 754-6.
  43. Issels RD, Lindner LH et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncology. 2010;11(6):561-570.
  44. Issels RD, Lindner LH et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncology. 2018;4(4):483-492. 
  45. Fang H, Zhang Y et al. Regional hyperthermia combined with chemotherapy in advanced gastric cancer. Open Medicine (Warsaw, Poland). 2019;14:85-90.
  46. Chi MS, Yang KL et al. Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful boney metastases: a phase 3 prospective, randomized, controlled trial. International Journal of Radiation Oncology, Biology, Physics. 2018;100(1):78-87.
  47. Pang CLK, Zhang X et al. Local modulated electro-hyperthermia in combination with traditional Crinese medicine vs. intraperitoneal chemoinfusion for the treatment of periotoneal carcinomatosis with malignant ascites: a phase II randomized trial. Molecular and Clinical Oncology. 2017;6(5):723-732.
  48. Foster JM, Sleightholm R et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Network Open. 2019 Jan 4;2(1):e186847.
  49. Li Y, Zhou YF et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World Journal of Gastroenterology. 2016 Aug 14;22(30):6906-16.
  50. Quénet F, Elias D et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan 18:S1470-2045(20)30599-4.
  51. Polom K, Roviello G et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. International Journal of Hyperthermia. 2016 May;32(3):298-310.
  52. Cascales-Campos P, Gil J, Feliciangeli E, Parrilla P. HIPEC in ovarian cancer: treatment of a new era or is it the end of the pipeline? Gynecologic Oncology. 2015 Nov;139(2):363-8.
  53. Hotouras A, Desai D et al. Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. International Journal of Gynecological Cancer. 2016 May;26(4):661-70.
  54. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. European Journal of Surgical Oncology. 2015 Dec;41(12):1578-89.
  55. Jewell A, McMahon M, Khabele D. Heated intraperitoneal chemotherapy in the management of advanced ovarian cancer. Cancers (Basel). 2018 Sep 1;10(9). pii: E296.
  56. Kireeva GS, Gafton GI et al. HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes. Surgical Oncology. 2018 Jun;27(2):251-258.
  57. .Chua TC, Robertson G et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. Journal of Cancer Research and Clinical Oncology. 2009 Dec;135(12):1637-45.
  58. Ryu KS, Kim JH et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecologic Oncology. 2004 Aug;94(2):325-32.
  59. Di Giorgio A, Naticchioni E et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008 Jul 15;113(2):315-25.
  60. van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New England Journal of Medicine. 2018 Apr 5;378(14):1363-1364.
  61. Helm CW, Richard SD et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. International Journal of Gynecological Cancer. 2010 Jan;20(1):61-9.
  62. Zhou H, Wu W, Tang X, Zhou J, Shen Y. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jan;96(1):e5532.
  63. Patel MD, Damodaran D et al. Hyperthermic intrathoracic chemotherapy (HITHOC) for pleural malignancies—experience from Indian centers. Indian Journal of Surgical Oncology. 2019 Feb;10(Suppl 1):91-98.
  64. Liu XL, Ma F et al. [Therapeutic effect of whole body hyperthermia combined with chemotherapy in patients with advanced cancer]. [Article in Chinese] Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Jun;31(3):350-2.
  65. Robins HI, Cohen JD, Schmitt CL Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology. 1993 Sep;11(9):1787-94.
  66. Robins HI, Longo WL et al. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Research. 1988 Nov 15;48(22):6587-92.
  67. Atanackovic D, Pollok K et al. Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2006 Mar;290(3):R585-94.
  68. Kleef R, Moss R et al. Complete clinical remission of stage IV triple-negative breast cancer lung metastasis administering low-dose immune checkpoint blockade in combination with hyperthermia and interleukin-2. Integrative Cancer Therapies. 2018 Sep 7:1534735418794867.
  69. Richel O, Zum Vörde Sive Vörding PJ et al. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecologic Oncology. 2004;95(3):680-685.
  70. Hegewisch-Becker S, Gruber Y et al. Whole-body hyperthermia (41.8 C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Annals of Oncology. 2002;13(8):1197–1204.
  71. Hildebrandt B, Drager J et al. Whole-body hyperthermia in the scope of von Ardenne’s systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. International Journal of Hyperthermia. 2004;20(3):317–333.
  72. Hegewisch-Becker S, Gruber Y et al. Whole-body hyperthermia (41.8 C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Annals of Oncology. 2002;13(8):1197–1204.;Hildebrandt B, Drager J et al. Whole-body hyperthermia in the scope of von Ardenne’s systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. International Journal of Hyperthermia. 2004;20(3):317–333.
  73. Engelhardt R, Muller U, Weth-Simon R, Neumann HA, Lohr GW. Treatment of disseminated malignant melanoma with cisplatin in combination with whole-body hyperthermia and doxorubicin. International Journal of Hyperthermia. 1990;6(3):511–515.
  74. Bakhshandeh A, Bruns I et al. Ifosfamide, carboplatin and etoposide combined with 41.8degreeC whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 2003;39(3):339–345.
  75. Douwes F, BogoviC J, Douwes O, Migeod F, Grote C. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer. International Journal of Clinical Oncology. 2004 Apr;9(2):85-91.
  76. Westermann AM, Grosen EA et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. European Journal of Cancer. 2001 Jun;37(9):1111-7.
  77. Cohen JD, Robins HI. Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer. Advances in Experimental Medicine and Biology. 1990;267:197-202.
  78. Atmaca A, Al-Batran SE et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer—a phase II study. Gynecologic Oncology. 2009 Feb;112(2):384-8.
  79. Kleef R, Kekic S, Ludwig N. Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy. Case Reports in Oncology. 2012 May;5(2):212-5.
  80. Bakshandeh-Bath A, Stoltz AS et al. Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Research. 2009;29(8):3069–3077.
  81. Bull JM, Cronau LH et al. Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU. International Journal of Hyperthermia. 1992;8(3),297–304.
  82. Wiedemann GJ, Robins HI et al. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. European Journal of Cancer. 1996;32a(5):888–892.
  83. Westermann AM, Wiedemann GJ et al. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma. Oncology 2003;64(4):312–321.
  84. Masuda H, Tanaka T, Matsushima S. Hyperthermic enhancement of cisplatin-induced generation of active oxygen radicals in a cell-free system. Anticancer Research. 1998 May-Jun;18(3A):1473-7.
  85. Strebel FR, Proett JM, Rowe RW, Wanleng D, Bull JMC. Effect of oxaliplatin combined with fever-range whole body thermal-therapy in a rat mammary adenocarcinoma in vivo. Proceedings of the American Association for Cancer Research. 2006 Apr;66(8); Matsuda H, Strebel FR et al. Long duration-mild whole body hyperthermia of up to 12 hours in rats: feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: implications for adjuvant therapy. International Journal of Hyperthermia. 1997;13(1):89-98; Toyota N, Strebel FR, Stephens LC, Matsuda H, Bull JM. Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis in a metastatic rat mammary adenocarcinoma. International Journal of Hyperthermia. 1997;13(5):497-506; Bull J, Loo C et al. Treatment of a highly metastatic mammary adenocarcinoma with fever-range, long-duration, low-temperature (40C for 6h) whole body hyperthermia (LL-WBH) combined with gemcitabine (dFdC) in rats. Proceedings of the American Association for Cancer Research. 1999;40:552 (Abstract 3643).
  86. Repasky EA, Tims E, Pritchard M, Burd R. Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice. Infectious Diseases in Obstetrics and Gynecology. 1999;7(1-2):91-7.
  87. Repasky EA, Tims E, Pritchard M, Burd R. Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice. Infectious Diseases in Obstetrics and Gynecology. 1999;7(1-2):91-7.
  88. Brockow T, Wagner A, Franke A, Offenbächer M, Resch KL. A randomized controlled trial on the effectiveness of mild water-filtered near infrared whole-body hyperthermia as an adjunct to a standard multimodal rehabilitation in the treatment of fibromyalgia. Clinical Journal of Pain. 2007 Jan;23(1):67-75.
  89. Rajeev R, Klooster B, Turaga KK. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Journal of Gastrointestinal Oncology. 2016 Feb;7(1):122-8.
  90. Rajeev R, Klooster B, Turaga KK. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Journal of Gastrointestinal Oncology. 2016 Feb;7(1):122-8.
  91. Rajeev R, Klooster B, Turaga KK. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Journal of Gastrointestinal Oncology. 2016 Feb;7(1):122-8.
  92. Foster JM, Sleightholm R et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Network Open. 2019 Jan 4;2(1):e186847.
  93. Partain KN, Gabriel E et al. Outcomes after CRS-HIPEC by facility: do higher volumes matter? Academic Surgical Congress Abstracts Archive. 2018.
  94. American Cancer Society: Hyperthermia to Treat Cancer. May 3, 2016. Viewed April 22, 2019; Issels RD, Lindner LH et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncology. 2010;11(6):561-570..
  95. Oncology Nurse Advisor. Hyperthermia in Cancer Treatment (Fact Sheet). November 7, 2013. Viewed April 24, 2019.
  96. Hebert ME, Blivin JL, Kessler J, Soper JT, Oleson JR. Anaphylactoid reactions with intraperitoneal cisplatin. Annals of Pharmacotherapy. 1995 Mar;29(3):260-3.
  97. Atmaca A, Al-Batran SE et al.Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer—a phase II study. Gynecologic Oncology. 2009 Feb;112(2):384-8; Issels RD, Lindner LH et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncology. 2010;11(6):561-570..
  98. Ohno S, Strebel FR et al. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. British Journal of Cancer. 1993;68(3):469-474.
  99. Yurttas C, Hoffmann G et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. Journal of Clinical Medicine. 2018 Dec 19;7(12). pii: E567. 
  100. McKinney N. Naturopathic Oncology, Fourth Edition. Victoria, BC, Canada: Liaison Press. 2020.